Plain-English translation of NCT06875193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether dapagliflozin — a medication that helps your kidneys remove extra sugar through urine — or pioglitazone — a medication that helps your body use insulin better — can improve blood sugar control when added to the diabetes medications you're already taking. Researchers want to see if either medication is more helpful and safe for people with type 2 diabetes whose blood sugar isn't fully controlled on their current treatment.
Many people with type 2 diabetes need more than one medication to keep their blood sugar in a healthy range. This study is designed to find out whether adding one of these two medications to a patient's current treatment plan works better and causes fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of two medication combinations: either dapagliflozin combined with sitagliptin, or pioglitazone combined with sitagliptin — alongside the metformin and DPP-4 inhibitor you're already taking. You will visit the research center multiple times so doctors can check your blood sugar levels, overall health, and how well the medication is working, along with any side effects you may experience.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
South Korea
Phase
Post-approval monitoring
Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Enrollment target
~196 participants
Started
May 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.